Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer at EMSO 2019